Related Experiment Video
Updated: Jul 16, 2026

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
[Lung toxicity induced by rapamycin]
C Damas1, A Oliveira, A Morais
1Serviço de Pneumologia, Hospital de São João, Alameda Hernâni Monteiro, 4200-451 Porto.
Abstract:
Drug induced lung diseases (DILD) are an increasing cause of morbidity. Many drugs have been described, causing several patterns of injury. Sirolimus is an immunosuppressive agent increasingly used in renal and other solid organ transplantation. Pulmonary toxicity has been recognised as a potential complication associated to this medication. Interstitial pneumonitis and more rarely alveolar haemorrhage have been described. The authors describe 4 cases (3 men and 1 woman) between 46-71 years, transplanted three years ago (1 patient) and 7 years ago (3 patients). All of them were medicated with micofenolato mofetil, prednisone and sirolimus. All patients had fever at admission, 3 patients had dyspnoea and 2 productive cough. Diffuse pulmonary infiltrates with basal predominance in HRCT scan were present in the four patients. BAL showed lymphocytic alveolitis in 3 cases, however with a different CD4/CD8 ratio. In addition to lymphocytosis, neutrophilia was observed in 2 patients. One patient showed serious alveolar haemorrhage in BAL. Pulmonary infections were ruled out by specific BAL staining and cultures. After drug suspension, all patients showed a clear improvement. These case studies show some diversity in clinical presentation and in the features of some exams, namely in BAL. This may suggest different underlying pathophysiology entities induced by sirolimus.
Insights
Sirolimus can cause drug-induced lung diseases (DILD) in transplant patients, presenting diverse symptoms and HRCT findings. Early drug withdrawal led to significant improvement, suggesting varied sirolimus-related lung injury mechanisms.
Area of Science:
- Pulmonology
- Pharmacology
- Transplantation Medicine
Background:
- Drug-induced lung diseases (DILD) represent a growing cause of morbidity.
- Sirolimus, an immunosuppressant, is increasingly used in solid organ transplantation.
- Pulmonary toxicity is a recognized complication of sirolimus therapy.
Observation:
- Four transplant recipients (3 male, 1 female; ages 46-71) developed lung issues.
- Patients presented with fever, dyspnea, and productive cough.
- HRCT scans revealed diffuse pulmonary infiltrates with basal predominance.
Findings:
- Bronchoalveolar lavage (BAL) showed lymphocytic alveolitis in 3 cases, with varying CD4/CD8 ratios.
- Two patients had neutrophilia, and one experienced alveolar hemorrhage.
- Pulmonary infections were excluded; drug suspension resulted in clinical improvement.
Implications:
- Sirolimus-induced lung injury can manifest with diverse clinical and BAL findings.
- These variations may indicate distinct underlying pathophysiological processes.
- Further research is needed to elucidate the mechanisms of sirolimus pulmonary toxicity.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Drug Toxicity: Dose-Dependent Reactions

